Skip to main content
. 2015 Feb 23;10(2):e0118210. doi: 10.1371/journal.pone.0118210

Fig 1. Investigating the effects of the vemurafenib and erlotinib combination in BRAF and KRAS mutant NSCLC cells.

Fig 1

A: Western blot of phosphorylated AKT and ERK signaling in native untreated cell lines ([+] mutated; [–] wildtype). All lanes are from the same gel and break was created to include only relevant cell lines B: A549, H460, H1755 and HCC364 cell lines treated with D (DMSO) or indicated drugs, E (erlotinib), V (vemurafenib), and EV (erlotinib-vemurafenib) were analyzed after 72h by a MTS assay. The IC50 for Vemurafenib in HCC364 was 0.8 μM. C: Western blot of different NSCLC cell lines, showing changes in p-ERK, p-AKT and PARP with vehicle D (DMSO), E (erlotinib) 1.6 μM, V (vemurafenib) 1.6 μM, EV (erlotinib+vemurafenib) 1.6/1.6, μM after 24h treatment. D: Apoptosis by flow cytometry 48h post treatment with D (DMSO), E (erlotinib) 1.6 μM, V (vemurafenib) 1.6 μM, EV (erlotinib/vemurafenib 1.6/1.6 μM). Western blot, post 48h, supporting PARP cleavage with V and EV in HCC364 but not H1755 cells.